Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
In the days, months and years ahead under a new US presidential administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention and in global health generally, and to safeguard policies and programs that advance it.
Blog Post
As we continue to grapple with the results of the US presidential election and what this means for our work and for global health evidence- and rights-based policies and programs generally, we wanted to share a range of new tools and resources you may find helpful in your advocacy for choice, science and rights.
Blog Post
We will all need time to process the US election results and strategize how we navigate through them in the years ahead — as individuals, as a network of partners, and as advocates for choice, science, and rights. We look forward to working with our partners in protecting hard-fought gains and assessing the potential impact on PEPFAR, Global Fund support, and on US government aid agencies.
showing 1-10 of 1047
In the days, months and years ahead under a new US presidential administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention and in global health generally, and to safeguard policies and programs that advance it.
As we continue to grapple with the results of the US presidential election and what this means for our work and for global health evidence- and rights-based policies and programs generally, we wanted to share a range of new tools and resources you may find helpful in your advocacy for choice, science and rights.
Prevention Option:
We will all need time to process the US election results and strategize how we navigate through them in the years ahead — as individuals, as a network of partners, and as advocates for choice, science, and rights. We look forward to working with our partners in protecting hard-fought gains and assessing the potential impact on PEPFAR, Global Fund support, and on US government aid agencies.
The past few months have brought exciting developments in the field of sexually transmitted infections. WHO released the global priorities for STIs, which included the need to develop low-cost, rapid STI point-of-care tests, vaccines, and communication strategies to increase STI awareness. But we continue to see a soaring rise in STI incidence and an underfunded infrastructure for researching new treatment, prevention and testing tools.
Prevention Option:
With the latest draft of the pandemic agreement released in September showing significant weaknesses and unresolved issues, negotiators face a time crunch at their upcoming November session in Geneva to either finalize terms by mid-November or extend talks into May 2025.
This week our Advocacy Chronicles podcast casts a spotlight on the state of HIV prevention among Black people in the US and particularly, the dismal statistics on access to PrEP in Black communities. The episode explores the tactics that have led PIBA to quickly rise as a powerhouse advocacy group by bringing together communities and government to find solutions that improve the US HIV response.
AVAC’s round-up of resources, updates and insights this week includes highlights from HIVR4P, a new vision for an inclusive prevention pipeline, shaping policy and more!
On the final day of HIVR4P 2024, we saw a focus on how to center communities from a number of angles—from the role of artificial intelligence in HIV prevention and details from a study on PrEP choices among African women to a manifesto for the inclusion of trans communities and a journalism initiative to translate HIV science into African languages.
At the plenary Back to the future, Sharonann Lynch of Georgetown University called for a transformational approach that would harness ambition and finally disrupt the “mediocre pace of scale-up” that squandered the global opportunity to leverage oral PrEP in 2012 and bend the curve of the epidemic. Read for more on this and all the other news from day four of R4P.
The data and discussions at HIVR4P 2024 in Lima, so far this week have been setting the stage for understanding what’s been accomplished in HIV prevention, understanding how choice works and why it matters, and where the research agenda is headed. But, as AVAC’s Mitchell Warren told Axios, “lenacapavir is on everybody’s lips here… That’s probably the second-most popular word this week. I think the most popular word is access.”
showing 1-10 of 1047
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.